Medifast, Inc. (MED) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed substantial challenges: a 36.9% revenue decline, a 40.6% drop in active coaches, and a net loss of $18.1 million. Despite some positive aspects like improved coach productivity and a focus on metabolic health, the lack of guidance on revenue stabilization and ongoing losses indicate financial strain. The restructuring efforts and regulatory risks add further uncertainty. The Q&A section highlighted management's vague responses, negatively impacting sentiment. These factors suggest a negative stock price reaction over the next two weeks.
Key Financial Performance
Revenue Fourth quarter 2025 revenue was $75.1 million, a decrease of 36.9% year-over-year, primarily driven by a decrease in the number of active earning coaches.
Active Earning Coaches The number of active earning coaches was approximately 16,100, a decrease of 40.6% from the fourth quarter of 2024. This decline was driven by the rapid adoption of GLP-1 medications and the exit of less productive coaches.
Revenue Per Active Earning Coach Average revenue per active earning coach for the fourth quarter was $4,664, a year-over-year increase of 6.2%. This increase was attributed to the exit of less productive coaches and the new coach leadership structure.
Gross Profit Gross profit for Q4 2025 decreased 40.9% year-over-year to $52.1 million, driven by lower sales volumes. Gross profit margin decreased 470 basis points to 69.4%, primarily due to the loss of leverage on fixed costs and a one-time restructuring charge.
SG&A Expense SG&A expense for Q4 2025 was $59.9 million, down 31.5% year-over-year, primarily due to decreases in coach compensation, marketing-related expenses, and employee base realignment. However, it increased as a percentage of revenue by 630 basis points due to fixed costs and restructuring charges.
Loss Per Share The loss per share for Q4 2025 was $1.65, impacted by a $12.1 million noncash valuation allowance against deferred tax assets, which represented $1.10 of the loss. Excluding this, the loss per share was $0.55.
Net Loss Net loss in Q4 2025 was $18.1 million compared to net income of $0.8 million in the year earlier period. The loss was driven by lower gross profit and a valuation allowance against deferred tax assets.
Cash and Investments The company ended the year with $167.3 million in cash, cash equivalents, and investment securities, and no debt.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New product line development: Medifast is leveraging its metabolic synchronization science platform to develop a new product line aimed at reducing visceral fat, improving body composition, metabolic efficiency, and overall health. These products will use a proprietary formula of clinically studied ingredients.
Market positioning: Medifast has repositioned itself as a metabolic health company, moving beyond traditional weight loss to address metabolic dysfunction. This shift targets a large underserved market, as 94% of American adults express concern about metabolic health, and 85% believe it can be reversed.
Coach productivity: Coach productivity turned positive for the first time since mid-2022, with a 6% year-over-year increase in Q4 2025. This is seen as a leading indicator of future growth.
Cost structure alignment: Medifast executed a restructuring to save over $30 million, aligning its cost structure with market realities while preserving resources for growth investments.
Strategic shift to metabolic health: Medifast transitioned from focusing solely on weight loss to addressing broader metabolic health issues, supported by clinical research and a coach-led model.
Leadership transition: CEO Dan Chard announced his planned departure in June 2026, with Nick Johnson expected to assume the role. This transition is part of a planned leadership change to ensure continuity in executing the company's strategy.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Leadership Transition: The planned transition of the CEO role from Dan Chard to Nick Johnson by June 2026 could pose risks related to leadership continuity and strategic execution during the handover period.
Market Disruption: The company has faced fundamental disruption in the weight loss industry due to the rapid adoption of GLP-1 medications and shifting consumer expectations, which has negatively impacted its traditional business model.
Coach Attrition: A significant decline in the number of active earning coaches (down 40.6% year-over-year) has been reported, which could hinder revenue growth and operational stability.
Revenue Decline: Revenue for Q4 2025 decreased by 36.9% year-over-year, primarily due to a reduction in active earning coaches, reflecting challenges in client acquisition and retention.
Profitability Challenges: The company reported a net loss of $18.1 million in Q4 2025, with ongoing losses expected in 2026, indicating financial strain and the need for cost management.
Operational Restructuring: Restructuring efforts, including scaling back marketing spend and reducing the employee base, aim to save $30 million but could disrupt operations and employee morale.
Regulatory and Market Risks: The company operates in a highly regulated and competitive market, which could pose challenges to its metabolic health-focused strategy and product development.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: First quarter 2026 revenue is expected to range from $65 million to $80 million. Full year 2026 revenue is projected to be between $270 million and $300 million.
Profitability Outlook: The company expects to make significant progress towards profitability in 2026, with improvements starting in Q4 2026 following the launch of a new product line. Earnings improvements are expected to continue into 2027 and beyond.
Coach Productivity: Continued growth in coach productivity is expected during Q1 2026, both year-over-year and sequentially. Sustained productivity improvements are anticipated to lead to revenue growth over several quarters.
New Product Launch: A new product line focused on metabolic health is planned for launch in Q4 2026, expected to support profitability improvements.
Market Positioning: The company is focusing on metabolic health as a key growth area, leveraging its metabolic synchronization science platform and coach-led model to address a large underserved market.
Cost Management: Targeted future savings of over $30 million have been incorporated into 2026 guidance through restructuring and scaling back marketing spend.
Working Capital: Working capital is expected to exceed $140 million by December 31, 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide details on coach productivity and the sequencing into 2026, particularly regarding the consumers matched with these coaches?
A:Daniel Chard explained that coach productivity has improved year-over-year for the first time since mid-2022. This improvement is attributed to coaches being retrained to focus on metabolic health, which resonates with a new type of customer seeking health benefits beyond weight loss. The company expects sustained and improved productivity as new products are introduced later this year. Additionally, significant cost structure improvements, including a $30 million reduction, are anticipated to positively impact the current year.
Q:Is it possible for revenues to stabilize or even turn positive by Q4, given the annual guidance provided?
A:Nicholas Johnson stated that while the company is not providing quarterly guidance, the annual guidance reflects confidence in the transition to metabolic health. He indicated that stabilization of the top line is anticipated, but did not confirm whether revenues would turn positive by Q4.
Q:How will the new product lineup and innovations address the changing composition of the consumer base, particularly those using or transitioning off GLP-1 drugs?
A:Daniel Chard noted that a significant portion of clients (approximately 25%) have used or are using GLP-1 drugs, and many are transitioning off these medications. The company is focusing on metabolic health and addressing issues like weight regain after stopping GLP-1 drugs. Nicholas Johnson added that the new program launching later this year will address concerns about body composition, emphasizing the reduction of visceral fat while preserving lean mass, which aligns with consumer priorities.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers to questions about quarterly revenue guidance and whether revenues would turn positive by Q4. Their responses lacked specific details and relied on general statements about confidence in the annual guidance and stabilization of the top line.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO
Premier EDGE
approach metabolic
behavior
belief
body composition
call
center
coach base
coach model
coach program
coach rank
cycle
decision
discipline
duplication
emergence
field
health story
indicator
market
metabolic dysfunction
metabolic health
metabolic process
metabolic synchronization
mid
opportunity meeting
profitability
reality
referral activity
reset
science coach
sign
symptom
system
transition
work year
MED Transcript
Medifast, Inc. (MED) Q4 2025 Earnings Call Transcript
Unknown2-17
The earnings call revealed substantial challenges: a 36.9% revenue decline, a 40.6% drop in active coaches, and a net loss of $18.1 million. Despite some positive aspects like improved coach productivity and a focus on metabolic health, the lack of guidance on revenue stabilization and ongoing losses indicate financial strain. The restructuring efforts and regulatory risks add further uncertainty. The Q&A section highlighted management's vague responses, negatively impacting sentiment. These factors suggest a negative stock price reaction over the next two weeks.
Medifast, Inc. (MED) Q3 2025 Earnings Call Transcript
Unknown11-3
The earnings call highlighted significant challenges, including a 36.2% revenue decline, increased SG&A expenses, and a net loss, indicating financial strain. Despite optimistic guidance on coach productivity and new programs, economic uncertainties and competition pose risks. The Q&A session revealed unclear management responses, adding to investor concerns. Although there are plans for product evolution and a focus on metabolic health, the lack of immediate positive catalysts and the absence of a market cap suggest a negative stock price movement in the short term.
Medifast, Inc. (MED) Q2 2025 Earnings Call Transcript
Unknown8-4
The earnings call revealed significant challenges: a 37.4% revenue decline, reduced coach productivity, and client acquisition pressures. Despite cost optimizations and no debt, the market faces economic uncertainties and competitive challenges from GLP-1 medications. Q&A insights did not mitigate these concerns, as reliance on GLP-1 was noted. While operational improvements and investment gains led to positive net income, the weak revenue guidance and coach network issues indicate a negative short-term outlook, likely resulting in a stock price decline of -2% to -8%.
Medifast, Inc. (NYSE:MED) Q1 2025 Earnings Call Transcript
Unknown4-29
The earnings call presents a challenging scenario for Medifast, Inc. with significant declines in revenue, active coaches, and earnings. Despite some cost reduction efforts, the overall financial performance is weak, with missed EPS expectations and a negative outlook. The Q&A session revealed management's inability to provide clear guidance, further contributing to uncertainty. The absence of a share repurchase program and the lack of significant positive catalysts suggest a negative market reaction in the near term.
MED Slides
MED Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
